Australia's Pharmaxis soars on U.S. FDA nod for mid-stage study of cancer drug

Syntara

09/11/2021 02:13

** Shares of Pharmaxis Ltd  PXS.AX  climb as much as 13.54%
to A$0.125 after U.S. FDA clears its cancer drug to progress to
phase-2 study 
    ** Stock eyes best session since Aug. 16; hits a week's high
    ** Co says FDA cleared the Investigational New Drug
application for a trial of PXS‐5505 in liver cancer  urn:newsml:reuters.com:*:nASX7BMzKH
    ** ~1.5 mln shares have changed hands vs 30-day avg of
~388,000 shares 
    ** PXS up 18.28% so far this year, as of Monday's close 

 (Reporting by Harshita Swaminathan in Bengaluru)
 ((Harshita.Swaminathan@thomsonreuters.com))